Overview

This trial is active, not recruiting.

Condition pancreatic cancer
Treatments gem-ox, gem-5fu, gem-tax, modified folfox-6, ox-tax, folfiri, tax-iri
Phase phase 2
Sponsor Georgetown University
Start date December 2012
End date June 2016
Trial size 20 participants
Trial identifier NCT01888978, 2011-384

Summary

This study is for patients with metastatic pancreatic cancer (cancer that has spread to other parts of the body). The purpose of this study is to determine whether molecularly tailored therapy can improve the effectiveness of standard chemotherapy combinations for patients with metastatic pancreatic cancer. A series of special tests will be performed on a sample of tumor, and based on the results subjects will be assigned to one of seven chemotherapy treatments, with each being the combination of two standard chemotherapies. Each of these combinations has been safely used in patients with pancreatic or other types of cancer. The purpose of this study is to to determine the ability to personalize therapy in this manner, and to determine how many patients a larger study would need. A second purpose is not to determine if one doublet is better than another. Rather, this second purpose is to show that for all patients enrolled in this protocol who have been assigned a doublet based on their tumor's molecular analysis (molecular tailoring), treatment response will be better than would be expected compared to patients who have been treated in the past with no molecular tailoring.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Oxaliplatin 85 mg/m2 day 1 and 5-fluorouracil 400 mg/m2 day 1 and Leucovorin 400 mg/m2 day 1 and 5-fluorouracil 2400 mg/m2 over 46 hours on day 1-3 of every 14 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed
modified folfox-6 Oxaliplatin
(Experimental)
Docetaxel 65 mg/m2 and Oxaliplatin 100 mg/m2 on day 1 every 3 weeks All drugs will be administered until disease progression or unacceptable toxicity are observed
ox-tax Docetaxel
(Experimental)
Irinotecan 180 mg/m2 on day 1 and 5-FU 400 mg/m2 on day 1 and Leucovorin 400 mg/m2 day 1 and 5-FU 2400 mg/m2 over 46 hours, days 1-3 as a continuous infusion All drugs will be administered until disease progression or unacceptable toxicity are observed
folfiri Irinotecan
(Experimental)
2 weeks on, 1 week off of Docetaxel 35 mg/m2/week and Irinotecan 50 mg/m2/week Both administered on day 1 of each week of treatment All drugs will be administered until disease progression or unacceptable toxicity are observed
tax-iri Docetaxel
(Experimental)
Gemcitabine: 1000 mg/m2 over 100 minutes on Day 1 Oxaliplatin: 100 mg/m2 over 120 minutes on Day 2 of every 14 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed
gem-ox Gemcitabine
(Experimental)
Gemcitabine: 1000 mg/m2 over 30 minutes 5-FU 2000/m6 as a 24 hour infusion on days 1, 8, and 15 of every 28 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed
gem-5fu Gemcitabine
(Experimental)
Gemcitabine 1000 mg/m2 over 30 minutes and Docetaxel 35 mg/m2 over 60 minutes on days 1, 8, and 15 of every 28 day cycle
gem-tax Gemcitabine

Primary Outcomes

Measure
Timing of biopsy and treatment
time frame: 1 year

Secondary Outcomes

Measure
Estimates for future trials
time frame: 1 year
Clinical Benefit
time frame: 1 year
Progression-free survival
time frame: 1 year

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Histologically proven pancreatic adenocarcinoma with measurable disease - Biopsy accessible tumor deposits - ECOG performance status 0-2 - Age >/= 18 years - Subjects with no brain metastases or history of previously treated brain metastases - Adequate hepatic, renal, and bone marrow function - Partial thromboplastin time must be 12 weeks - Women of childbearing potential must have a negative seum pregnancy test within 14 days prior to initiation of treatment - Subject is capable of understanding and complying with parameters as outlines in the protocol and able to sign and date the consents Exclusion Criteria: - CNS metastases which do not meet criteria outlines in inclusion criteria - Active severe infection or known chronic infection with HIV or hepatitis B virus - Cardiovascular disease - Life threatening visceral disease or other severe concurrent disease - Women who are pregnant, breastfeeding, or women of childbearing potential not using dual forms of effective contraception - Anticipated patient survival under 3 months - Patients receiving any other investigational agents - History of allergic reactions attributed to compounds of similar chemical or biological composition to gemcitabine, oxaliplatin, 5-FU, docetaxel or irinotecan - Uncontrolled intercurrent illness

Additional Information

Official title A Pilot Study of Molecularly Tailored Therapy for Patients With Metastatic Pancreatic Cancer
Principal investigator Michael Pishvaian, MD
Trial information was received from ClinicalTrials.gov and was last updated in February 2016.
Information provided to ClinicalTrials.gov by Georgetown University.